2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 1.
By phase and status
Follow Open Label: new trials by email Literature Review of Open Label trials Research Report on Open Label
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
REC617 - Phase 1b, Open Label | Phase 1 | Recruiting | 15 | 2026-10-19 | 2026-07-31 |
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
TNX-102 SL Tablet - Pharmakokinetic, Open Label | Phase 1 | Active not recruiting | 50 | 2025-12-09 | 2026-02-17 |
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab) - Advanced Urothelial Carcinoma, Oral Drug Administration | Phase 1 | Active not recruiting | 120 | 2023-08-24 | 2026-08-12 |
A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers
CAZ-AVI, CXL - Pharmacokinetics, Open Label | Phase 1 | Completed | 48 | 2013-08-01 | 2017-09-05 |
Narrower conditions
Leiomyosarcoma (1)
Broader conditions
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Muscle Tissue (1) · Sarcoma (1)
Interventions
KPNA1 protein, human (1) · pembrolizumab (1)
Sponsors
Flare Therapeutics Inc. (1) · M.D. Anderson Cancer Center (1) · Pfizer (1) · Tonix Pharmaceuticals, Inc. (1)
Countries
United States (2) · Canada (1) · Sweden (1)
Top investigators
Dan Rudin, MD (1) · Elise Nassif, MD (1) · Georgios Panagiotidis, MD (1) · Gopa Iyer, MD (1) · Paul Newell, MD (1) · Sandhia Ponnarambil, MD (1)
Results publications
PMID 41760953